TG Therapeutics reports Q1 BRIUMVI net sales of $7.8M in first partial launch quarter

TG THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.28 revenue$7,803,000

BRIUMVI net sales $7.8M for Q1 2023; over 400 prescriptions from 165+ HCPs at 125+ centers.
Payor coverage in place for over 50% of covered lives; permanent J-code effective July 1, 2023.
Net loss narrowed to $39.2M vs $69.0M YoY; cash $139.7M with $20M credit facility, funding into mid-2024.
CHMP positive opinion for EU approval of BRIUMVI for RMS; additional data presented at ACTRIMS/AAN.
R&D expense $15.9M (down from $48M) driven by lower manufacturing/clinical costs post-approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.